As the first company to introduce tablet-based allergy immunotherapy, ALK has demonstrated its leadership position within immunotherapy innovation.
In 2007, the company launched GRAZAX® the first registered allergy tablet.
Tablets are a convenient and popular way for patients to take treatment and it is expected that the availability of tablet vaccines will allow many more patents suffering from allergy to benefit from immunotherapy.